418P Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer

• DOI: 10.1016/j.annonc.2023.09.595
• Publication Date: 2023-10-20T11:34:52Z
• Authors: Q. Zhang; J. Wang; Q. Ouyang; X. Wang; D. Lin; J. Wang; L. Gan; Z. Ouyang; T. Xu; Y. Liu; Y. Lv
• Keywords: Pertuzumab; Tolerability; Clinical endpoint